Breadcrumb

null Catalin Mihalcioiu, MD, FRCP

Investigator, RI-MUHC, Glen site

Cancer Research Program

Assistant Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Medical Oncology, MUHC

 

Keywords

circulating tumor cells (CTC) • tumor stem cells • epithelial mezenchimal transformed cells • breast cancer • melanoma • prostate cancer

Research Focus

My research focuses on the isolation and characterization of circulating tumor cells (CTC) in the peripheral blood of patients with breast, melanoma and prostate cancer, to better understand the metastatic process and to be able to determine evolving predictive and prognostic markers in adjuvant and advanced settings in real time. My goal is to identify a methodology that allows for the collection of large numbers of CTCs from patients with early and advanced cancer, separate them in subgroups based on their epithelial, stem cell and mezenchimal profile, put them in culture, do CTC mouse inoculation, followed by in-depth analysis at the genome level to identify potential therapeutic targets and the creation of drug testing platforms. Other interests include immune system recognition of the CTCs by looking at Treg and DNA metylation of Tcells. I have also developed a Research Electronic Data Base called ATLAS for breast cancer and melanoma patients, which will ease clinical research.

Selected Publications

Click on Pubmed to see my current publications list

  • Stephen K. L. Chia, Susan Ellard, Mihaela Mates, Stephen Welch, Catalin Liviu Dragos Mihalcioiu, Wilson H. Miller, Karen A. Gelmon, Caroline A. Lohrisch, Vikaash Kumar, Sara Kristina Taylor, Linda Hagerman, Elizabeth A. Eisenhauer and Penelope Ann Bradbury. A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198. Journal of Clinical Oncology, 2013 ASCO Annual Meeting Abstracts.Vol 31, No 15_suppl (May 20 Supplement), 2013: 518

  • Teresa M. Petrella, Catalin Liviu Dragos Mihalcioiu, Elaine McWhirter, Karl Belanger, Kerry J. Savage, Xinni Song, Omid Hamid, Tina Cheng, Mary L. Davis, Christopher W Lee, Alan Spatz, Jose Gerard Monzon, Linda Hagerman, Bingshu E Chen, Janet Dancey; Odette Cancer Centre, Sunnybrook Health Sciences Centre; University of Toronto, Toronto, ON, Canada; Royal Victoria Hospital, Montreal, QC, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada; Hopital Notre-Dame, Montreal, QC, Canada; Department of Medical Oncology, British Columbia Cancer Agency Centre, Vancouver, BC, Canada; The Ottawa Hospital Cancer Center, Ottawa, ON, Canada; The Angeles Clinic and Research Institute, Santa Monica, CA; Tom Baker Cancer Centre, Calgary, AB, Canada; QEII Health Sciences Center, Halifax, NS, Canada; BC Cancer Agency, Fraser Valley Centre, Surrey, BC, Canada; Lady Davis Institute for Medical Research, Montreal, QC, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Kingston, ON, CanadaFinal efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM) J Clin Oncol 31, 2013 (suppl; abstr 9032)

  • Adriana Aguilar-Mahecha, Josiane Lafleur, Carole Seguin, Catalin Liviu Dragos Mihalcioiu, Josee-Anne Roy, Christine Desbiens, Andre Robidoux, Zuanel Diaz, Manuela Pelmus, Gerald Batist, Mark Basik, Quebec Clinical Research Organisation in Cancer; Segal Cancer Center/Jewish General Hospital, McGill University, Montreal, QC, Canada; Segal Cancer Center/Jewish General Hospital, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada; Royal Victoria Hospital, Montreal, QC, Canada; Hopital Sacré Coeur de Montreal, Montreal, QC, Canada; Hopital Saint Sacrement, Quebec, QC, Canada; NSABP and CHUM-Hotel Dieu, Montreal, QC, Canada; Q-CROC, Segal Cancer Centre, Montreal, QC, Canada; McGill University and Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada; Segal Cancer Centre/Jewish General Hospital, McGill University, Montreal, QC, CanadaQ-CROC-03: A prospective biopsy driven clinical trial to study the mechanisms of resistance to chemotherapy in triple-negative breast cancer patients. J Clin Oncol 30, 2012 (suppl; abstr TPS1139

  • Adriana Aguilar-Mahecha, Josiane Lafleur, Elaheh Ahmadzadeh, Ewa Przybytkowski, Carole Seguin, Catalin Liviu Dragos Mihalcioiu, Josee-Anne Roy, Christine Desbiens, Andre Robidoux, Elizabeth A. Marcus, Zuanel Diaz, Manuela Pelmus, Gerald Batist, Mark Basik, Quebec Clinical Research Organization in Cancer. Biopsy-driven study to identify biomarkers of drug resistance in patients with triple-negative breast cancer J Clin Oncol 30: 2012 (suppl 30; abstr 87)

  • Maria Ait-tihyaty, Catalin Mihalcioiu, Zakaria Rachid, Bertrand J Jean-Claud. Inhibition of EGFR phosphorilation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda. Breast cancer research and treatment 2012;133(1)217-26